Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3W2O

EGFR Kinase domain T790M/L858R Mutant with TAK-285

3W2O の概要
エントリーDOI10.2210/pdb3w2o/pdb
関連するPDBエントリー3POZ 3W2P 3W2Q 3W2R 3W2S
分子名称Epidermal growth factor receptor, N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide (3 entities in total)
機能のキーワードanti-oncogene, cell cycle, disease mutation, kinase domain, receptor, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数1
化学式量合計38568.93
構造登録者
Sogabe, S.,Kawakita, Y.,Igaki, S. (登録日: 2012-12-03, 公開日: 2013-01-16, 最終更新日: 2023-11-08)
主引用文献Sogabe, S.,Kawakita, Y.,Igaki, S.,Iwata, H.,Miki, H.,Cary, D.R.,Takagi, T.,Takagi, S.,Ohta, Y.,Ishikawa, T.
Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors.
Acs Med.Chem.Lett., 4:201-205, 2013
Cited by
PubMed Abstract: The epidermal growth factor receptor (EGFR) family plays a critical role in vital cellular processes and in various cancers. Known EGFR inhibitors exhibit distinct antitumor responses against the various EGFR mutants associated with nonsmall-cell lung cancer. The L858R mutation enhances clinical sensitivity to gefitinib and erlotinib as compared with wild type and reduces the relative sensitivity to lapatinib. In contrast, the T790M mutation confers drug resistance to gefitinib and erlotinib. We determined crystal structures of the wild-type and T790M/L858R double mutant EGFR kinases with reversible and irreversible pyrrolo[3,2-d]pyrimidine inhibitors based on analogues of TAK-285 and neratinib. In these structures, M790 adopts distinct conformations to accommodate different inhibitors, whereas R858 allows conformational variations of the activation loop. These results provide structural insights for understanding the structure-activity relationships that should contribute to the development of potent inhibitors against drug-sensitive or -resistant EGFR mutations.
PubMed: 24900643
DOI: 10.1021/ml300327z
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.35 Å)
構造検証レポート
Validation report summary of 3w2o
検証レポート(詳細版)ダウンロードをダウンロード

226707

件を2024-10-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon